These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2742312)

  • 21. Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients.
    Bauernfeind A; Hörl G; Przyklenk B
    Scand J Gastroenterol Suppl; 1988; 143():99-102. PubMed ID: 3164518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of cystic fibrosis in a Japanese student].
    Nakanishi N; Ueda N; Kitade M; Moritaka T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jul; 33(7):771-4. PubMed ID: 7564006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pseudomonas aeruginosa and mucoviscidosis].
    Lenoir G
    Rev Pneumol Clin; 1995; 51(3):151-9. PubMed ID: 7569577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the efficacy of sequential intravenous-oral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions.
    Yap JC; Wang YT; Chan CC; Ng A; Poh SC
    Singapore Med J; 1995 Oct; 36(5):484-6. PubMed ID: 8882529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolones in children: poorly defined risk of joint damage.
    Prescrire Int; 2004 Oct; 13(73):184-6. PubMed ID: 15499700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.
    Sendzik J; Lode H; Stahlmann R
    Int J Antimicrob Agents; 2009 Mar; 33(3):194-200. PubMed ID: 18835137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis].
    Anzaudo MM; Busquets NP; Ronchi S; Mayoral C
    Rev Argent Microbiol; 2005; 37(3):129-34. PubMed ID: 16323660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
    Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
    Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Respiratory infection in cystic fibrosis: burden of illness in the progression of cystic fibrosis, previous deductions for the microbiological study of bronchial secretions and clinical criteria of infection].
    Thumerelle C
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S37-48. PubMed ID: 12910133
    [No Abstract]   [Full Text] [Related]  

  • 32. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
    Nichols L; Maki DG
    Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cystic fibrosis: current therapy. Antibiotics].
    Tamm M; Héritier F; Rappaz I; Schaad UB
    Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469
    [No Abstract]   [Full Text] [Related]  

  • 34. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pefloxacin in the treatment of lower respiratory tract infections].
    Dericoloso A; Tranchese D; Bianco A; Cuccurullo S; Moro RA; Micillo E
    Arch Monaldi Mal Torace; 1990; 45(1):21-9. PubMed ID: 1669257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
    Schaad UB; Stoupis C; Wedgwood J; Tschaeppeler H; Vock P
    Pediatr Infect Dis J; 1991 Oct; 10(10):723-9. PubMed ID: 1945573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of bacterial resistance to pefloxacine after prolonged use in resuscitation].
    Malacarne P; Casagli S; Kaisserli P
    Minerva Anestesiol; 1992; 58(1-2):1-5. PubMed ID: 1589059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia].
    Postnikov SS; Semykin SIu; Kapranov NI; Perederko LV; Polikarpova SV; Khamidullina KF
    Antibiot Khimioter; 2000; 45(8):25-30. PubMed ID: 10989721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Joint manifestations of pefloxacin in adolescents].
    Seigneuric C; Plantavid M; Bouygues D; Cassou M; Amar J; Cascarigny F
    Presse Med; 1990 Mar; 19(9):428. PubMed ID: 2138767
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.
    Tatsis G; Tsoukalas G; Hatzinikolaou V; Boulbasakos G; Jordanoglou J
    J Int Med Res; 1996; 24(6):478-81. PubMed ID: 8959532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.